Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,294,092
  • Shares Outstanding, K 134,521
  • Annual Sales, $ 1,616 M
  • Annual Income, $ 515,840 K
  • 60-Month Beta 0.38
  • Price/Sales 0.80
  • Price/Cash Flow 2.49
  • Price/Book 0.77
Trade VIR with:

Options Overview Details

View History
  • Implied Volatility 62.01% ( -3.60%)
  • Historical Volatility 54.25%
  • IV Percentile 64%
  • IV Rank 24.11%
  • IV High 123.24% on 07/17/23
  • IV Low 42.56% on 08/07/23
  • Put/Call Vol Ratio 0.15
  • Today's Volume 92
  • Volume Avg (30-Day) 273
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 12,694
  • Open Int (30-Day) 12,882

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.14
  • Number of Estimates 5
  • High Estimate -0.98
  • Low Estimate -1.28
  • Prior Year -0.76
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.06 +19.35%
on 11/09/23
10.13 -5.03%
on 11/15/23
+1.03 (+11.99%)
since 11/08/23
3-Month
7.72 +24.61%
on 11/02/23
11.25 -14.49%
on 09/11/23
-1.38 (-12.55%)
since 09/08/23
52-Week
7.72 +24.61%
on 11/02/23
31.55 -69.51%
on 01/27/23
-16.18 (-62.71%)
since 12/08/22

Most Recent Stories

More News
From laggards to leaders: Small caps on the rise

Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.

MDY : 481.55 (+0.44%)
TSLA : 243.84 (+0.49%)
XLC : 70.48 (+0.47%)
IWM : 186.80 (+0.76%)
RCL : 120.47 (+0.82%)
XLK : 186.66 (+0.85%)
NVDA : 475.06 (+1.95%)
META : 332.75 (+1.89%)
SPSM : 39.23 (+0.54%)
SPY : 460.20 (+0.43%)
VIR : 9.62 (+0.31%)
RCUS : 15.77 (+0.83%)
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 0.4078 (-7.32%)
INSM : 27.96 (+1.41%)
VIR : 9.62 (+0.31%)
CODX : 1.2200 (unch)
ANTX : 18.79 (-0.05%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 27.96 (+1.41%)
VIR : 9.62 (+0.31%)
CODX : 1.2200 (unch)
ANTX : 18.79 (-0.05%)
ALBT : 0.4078 (-7.32%)
Is Vir Biotechnology Stock a Buy?

The biotech is out to prove that it isn't just a "pandemic stock."

VIR : 9.62 (+0.31%)
Why Shares of Vir Biotechnology Are Plunging Thursday

The company had disappointing trial news for one of its lead therapies.

GSK : 35.94 (-0.17%)
GILD : 79.02 (+1.24%)
VIR : 9.62 (+0.31%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 9.62 (+0.31%)
VBIV : 0.7102 (+2.36%)
ANTX : 18.79 (-0.05%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 9.62 (+0.31%)
VBIV : 0.7102 (+2.36%)
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -30.86% and 64.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

VIR : 9.62 (+0.31%)
RETA : 172.36 (+0.02%)
Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TWST : 26.98 (+2.16%)
VIR : 9.62 (+0.31%)
Earnings Preview: Vir Biotechnology, Inc. (VIR) Q1 Earnings Expected to Decline

Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VIR : 9.62 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 10.31
2nd Resistance Point 10.07
1st Resistance Point 9.85
Last Price 9.62
1st Support Level 9.39
2nd Support Level 9.15
3rd Support Level 8.93

See More

52-Week High 31.55
Fibonacci 61.8% 22.45
Fibonacci 50% 19.64
Fibonacci 38.2% 16.82
Last Price 9.62
52-Week Low 7.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar